Bicine

Bicine

SCHEMBL177696

O=C(O)CN(CCO)CCO.O=C(O)CN(CCO)CCO

nearest known ligand 0.68

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX15 P16050 3/20 0.68
TSHR P16473 3/20 0.68
TDP1 Q9NUW8 2/20 0.68
KDM4E B2RXH2 2/20 0.68
BLM P54132 2/20 0.68
PMP22 Q01453 2/20 0.68
LMNA P02545 2/20 0.68
CYP2C19 P33261 2/20 0.68
CHRM2 P08172 1/20 0.68
ADRA2A P08913 1/20 0.68
DRD1 P21728 1/20 0.68
SLC6A2 P23975 1/20 0.68
SLC6A4 P31645 1/20 0.68
ADRA1A P35348 1/20 0.68
DRD3 P35462 1/20 0.68
SLC6A3 Q01959 1/20 0.68
HRH3 Q9Y5N1 1/20 0.68
EYA2 O00167 1/20 0.63
APP P05067 1/20 0.63
ACE P12821 1/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bicine SCHEMBL34161 1.00 ALOX15 (0.68) ALOX15TSHRTDP1KDM4EBLM
Bicine SCHEMBL30968399 0.97 TDP1 (0.65) ALOX15TSHRTDP1KDM4EBLM
Bicine SCHEMBL20471950 0.97 ALOX15 (0.65) ALOX15TSHRTDP1KDM4EBLM
Bicine SCHEMBL30489348 0.97 ALOX15 (0.65) ALOX15TSHRTDP1KDM4EBLM
SCHEMBL8968107 0.97 TDP1 (0.74) ALOX15TSHRTDP1KDM4EBLM
Bicine SCHEMBL5065705 0.97 ALOX15 (0.65) ALOX15TSHRTDP1KDM4EBLM
Bicine SCHEMBL3357098 0.97 ALOX15 (0.65) ALOX15TSHRTDP1KDM4EBLM
Bicine SCHEMBL1747701 0.97 ALOX15 (0.65) ALOX15TSHRTDP1KDM4EBLM
Bicine SCHEMBL5883443 0.97 ALOX15 (0.65) ALOX15TSHRTDP1KDM4EBLM
Bicine SCHEMBL3981657 0.97 ALOX15 (0.65) ALOX15TSHRTDP1KDM4EBLM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 195 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4684196-A1 METHODS FOR ANTIGEN RETRIEVAL OF A FIXED SAMPLE FOR MULTIPLE APPLICATIONS Resolve BioSciences GmbH (DE) 2026-01-28 EP claimed
WO-2024193972-A1 METHODS FOR ANTIGEN RETRIEVAL OF A FIXED SAMPLE FOR MULTIPLE APPLICATIONS RESOLVE BIOSCIENCES GMBH (DE) 2024-09-26 WO claimed
US-10786602-B2 Method for treating surface of implant OSSTEMIMPLANT CO., LTD. (KR) 2020-09-29 US claimed
WO-2020130684-A1 FILLER HAVING EXCELLENT FILLER PROPERTIES COMPRISING HYALURONIC ACID HYDROGEL 주식회사 엘지화학 2020-06-25 WO claimed
EP-2992908-A1 METHOD FOR TREATING SURFACE OF IMPLANT Osstemimplant Co., Ltd. (KR) 2016-03-09 EP claimed
US-20160058920-A1 Method for Treating Surface of Implant OSSTEMIMPLANT CO., LTD. (KR) 2016-03-03 US claimed
EP-2470877-A1 METHOD AND APPARATUS FOR ANTIGEN RETRIEVAL PROCESS General Electric Company (US) 2012-07-04 EP claimed
US-8067241-B2 Method and apparatus for antigen retrieval process GENERAL ELECTRIC COMPANY (US) 2011-11-29 US claimed
JP-2011525128-A 2011-09-15 JP claimed
EP-2310459-A2 IMPROVED CROSS-LINKED COMPOSITIONS Lifebond Ltd (IL) 2011-04-20 EP claimed
WO-2011025442-A1 METHOD AND APPARATUS FOR ANTIGEN RETRIEVAL PROCESS GENERAL ELECTRIC COMPANY (US) 2011-03-03 WO claimed
US-20110053171-A1 METHOD AND APPARATUS FOR ANTIGEN RETRIEVAL PROCESS GENERAL ELECTRIC COMPANY (US) 2011-03-03 US claimed
US-7220872-B2 Conversion of taxane molecules NATURAL PHARMACEUTICALS, INC. (US) 2007-05-22 US claimed
WO-2026099278-A1 NORMALIZING AND POOLING OF PCR-FREE SEQUENCING LIBRARIES F. HOFFMANN-LA ROCHE AG (CH) 2026-05-15 WO disclosed
WO-2026087220-A1 PREPARATION OF DNA LIBRARIES FOR NEXT GENERATION SEQUENCING USING Y-ADAPTERS MODIFIED WITH PHOSPHOROTHIOATE BONDS F. HOFFMANN-LA ROCHE AG (CH) 2026-04-30 WO disclosed
US-20260108887-A1 MICROFLUIDIC BEAD TRAPPING DEVICES AND METHODS FOR NEXT GENERATION SEQUENCING LIBRARY PREPARATION ROCHE SEQUENCING SOLUTIONS INC (US) 2026-04-23 US disclosed
EP-0804610-B1 STABILISED COENZYME SOLUTIONS AND THE USE THEREOF FOR THE DETERMINATION OF DEHYDROGENASES OR THE SUBSTRATES THEREOF IN AN ALKALINE MEDIUM ROCHE DIAGNOSTICS GMBH (DE) 1999-11-03 EP disclosed
EP-0804610-A1 STABILISED COENZYME SOLUTIONS AND THE USE THEREOF FOR THE DETERMINATION OF DEHYDROGENASES OR THE SUBSTRATES THEREOF IN AN ALKALINE MEDIUM Roche Diagnostics GmbH (DE) 1997-11-05 EP disclosed
WO-1997019190-A1 STABILISED COENZYME SOLUTIONS AND THE USE THEREOF FOR THE DETERMINATION OF DEHYDROGENASES OR THE SUBSTRATES THEREOF IN AN ALKALINE MEDIUM BOEHRINGER MANNHEIM GMBH (DE) 1997-05-29 WO disclosed
US-4397843-A Mannose-6-phosphate-low density protein reagent effective against hypercholesterolemia THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 1983-08-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260108887-A1 MICROFLUIDIC BEAD TRAPPING DEVICES AND METHODS FOR NEXT GENERATION SEQUENCING LIBRARY PREPARATION POLL, STUB1, POLH ALOX15 2620/4885TSHR 2785/4885TDP1 11/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.